LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

38.32 4.19

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

37.08

Max

38.79

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Peļņas marža	-1,582.642
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+10.55% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3B 5.2B
Iepriekšējā atvēršanas cena	34.13
Iepriekšējā slēgšanas cena	38.32

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. nov. 22:23 UTC

Iegādes, apvienošanās, pārņemšana

BHP Abandons Bid for Anglo American Following New Talks

2025. g. 23. nov. 22:16 UTC

Iegādes, apvienošanās, pārņemšana

Macquarie Proposes $7.5 Billion Takeover of Logistics Operator Qube

2025. g. 23. nov. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Macquarie Proposes $7.5B Takeover of Logistics Operator Qube

2025. g. 23. nov. 19:00 UTC

Peļņas

Dell, HP Inc., Alibaba, Zoom, Deere, and More Stocks to Watch This Week -- Barrons.com

2025. g. 23. nov. 00:50 UTC

Peļņas

Wall Street Goes on a Wild Ride: 'No One Was Expecting This' -- WSJ

2025. g. 22. nov. 10:30 UTC

Peļņas

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

2025. g. 22. nov. 10:30 UTC

Iegādes, apvienošanās, pārņemšana

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

2025. g. 22. nov. 09:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 22:42 UTC

Tirgus saruna

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 21:47 UTC

Tirgus saruna

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

2025. g. 21. nov. 21:43 UTC

Tirgus saruna

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

2025. g. 21. nov. 20:18 UTC

Tirgus saruna

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

2025. g. 21. nov. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

2025. g. 21. nov. 19:48 UTC

Tirgus saruna

Precious Metals Fall for the Week -- Market Talk

2025. g. 21. nov. 19:44 UTC

Peļņas

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

2025. g. 21. nov. 19:37 UTC

Tirgus saruna

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2025. g. 21. nov. 19:27 UTC

Tirgus saruna

Peļņas

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

2025. g. 21. nov. 19:20 UTC

Tirgus saruna

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

2025. g. 21. nov. 18:44 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

2025. g. 21. nov. 18:37 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

2025. g. 21. nov. 18:34 UTC

Tirgus saruna

Peļņas

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

2025. g. 21. nov. 18:28 UTC

Peļņas

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

2025. g. 21. nov. 18:03 UTC

Tirgus saruna

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. nov. 17:24 UTC

Tirgus saruna

Intuit Seen on Path to Increase Growth -- Market Talk

2025. g. 21. nov. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 21. nov. 17:05 UTC

Tirgus saruna

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

10.55% augšup

Prognoze 12 mēnešiem

Vidējais 40.64 USD 10.55%

Augstākais 65 USD

Zemākais 20 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.